Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $35.70 Average Price Target from Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve brokerages that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $35.70.

A number of brokerages have issued reports on VRDN. HC Wainwright reiterated a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Needham & Company LLC reiterated a "buy" rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th.

Viridian Therapeutics Stock Performance

Shares of NASDAQ:VRDN traded down $0.10 during trading on Wednesday, reaching $13.40. 356,153 shares of the stock were exchanged, compared to its average volume of 1,199,782. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $27.20. The stock has a 50-day moving average price of $14.24 and a 200-day moving average price of $18.21. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.09 billion, a PE ratio of -3.11 and a beta of 0.81.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Research analysts expect that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VRDN. Amalgamated Bank lifted its stake in shares of Viridian Therapeutics by 49.7% in the first quarter. Amalgamated Bank now owns 2,531 shares of the company's stock worth $34,000 after acquiring an additional 840 shares during the period. SG Americas Securities LLC increased its position in shares of Viridian Therapeutics by 2.9% during the first quarter. SG Americas Securities LLC now owns 31,972 shares of the company's stock worth $431,000 after buying an additional 887 shares during the period. Rhumbline Advisers raised its stake in Viridian Therapeutics by 4.6% during the first quarter. Rhumbline Advisers now owns 104,559 shares of the company's stock worth $1,409,000 after buying an additional 4,621 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Viridian Therapeutics by 3,892.9% in the first quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock valued at $114,000 after buying an additional 8,214 shares during the period. Finally, California State Teachers Retirement System raised its position in shares of Viridian Therapeutics by 18.0% in the 4th quarter. California State Teachers Retirement System now owns 54,710 shares of the company's stock worth $1,049,000 after acquiring an additional 8,344 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.